This prompts consideration of the cortical A2AR upregulation as a putative novel biomarker of the risk of developing AD [46], and eventually as a general biomarker of neuropsychiatric diseases [99] in view of the association of A2AR overfunction with different neuropsychiatric diseases [99]. This evidence concerns the gene ADORA2A and Alzheimer disease.